
Lei Yao
Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1328 |
| Issued Applications | 662 |
| Pending Applications | 127 |
| Abandoned Applications | 552 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13955595
[patent_doc_number] => 20190054141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-21
[patent_title] => MOLECULAR MARKER FOR CANCER STEM CELL
[patent_app_type] => utility
[patent_app_number] => 16/110001
[patent_app_country] => US
[patent_app_date] => 2018-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14814
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16110001
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/110001 | Molecular marker for cancer stem cell | Aug 22, 2018 | Issued |
Array
(
[id] => 13607547
[patent_doc_number] => 20180355323
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-13
[patent_title] => COMPOSITION FOR INDUCING DEDIFFERENTIATION INTO CANCER STEM CELLS COMPRISING RIBOSOME-ACTIVATING INHIBITOR AS ACTIVE INGREDIENT, CANCER ORGANOID CULTURE METHOD AND ANTICANCER DRUG SCREENING PLATFORM BASED THEREON
[patent_app_type] => utility
[patent_app_number] => 16/105978
[patent_app_country] => US
[patent_app_date] => 2018-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3747
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16105978
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/105978 | Composition for inducing dedifferentiation into cancer stem cells comprising ribosome-activating inhibitor as active ingredient, cancer organoid culture method and anticancer drug screening platform based thereon | Aug 20, 2018 | Issued |
Array
(
[id] => 16839538
[patent_doc_number] => 20210147550
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
[patent_app_type] => utility
[patent_app_number] => 16/639073
[patent_app_country] => US
[patent_app_date] => 2018-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 124241
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639073
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/639073 | ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS | Aug 16, 2018 | Abandoned |
Array
(
[id] => 13622213
[patent_doc_number] => 20180362658
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-20
[patent_title] => ESOPHAGEAL CANCER MARKER AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/103840
[patent_app_country] => US
[patent_app_date] => 2018-08-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48090
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16103840
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/103840 | ESOPHAGEAL CANCER MARKER AND USE THEREOF | Aug 13, 2018 | Abandoned |
Array
(
[id] => 16111691
[patent_doc_number] => 20200207868
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-02
[patent_title] => HER3 BINDING AGENTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/637201
[patent_app_country] => US
[patent_app_date] => 2018-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26707
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637201
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/637201 | HER3 binding agents and uses thereof | Aug 8, 2018 | Issued |
Array
(
[id] => 18567095
[patent_doc_number] => 20230257424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => BLOOD-BRAIN BARRIER TRANSMIGRATING COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/965885
[patent_app_country] => US
[patent_app_date] => 2018-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32349
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965885
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/965885 | BLOOD-BRAIN BARRIER TRANSMIGRATING COMPOUNDS AND USES THEREOF | Jul 30, 2018 | Abandoned |
Array
(
[id] => 16613711
[patent_doc_number] => 20210032364
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/634022
[patent_app_country] => US
[patent_app_date] => 2018-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54590
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -108
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16634022
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/634022 | ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCER | Jul 25, 2018 | Abandoned |
Array
(
[id] => 16806060
[patent_doc_number] => 20210128613
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => ENGINEERED IMMUNE CELLS RESISTANT TO TUMOR MICROENVIRONMENT
[patent_app_type] => utility
[patent_app_number] => 16/629506
[patent_app_country] => US
[patent_app_date] => 2018-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26973
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16629506
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/629506 | Engineered immune cells resistant to tumor microenvironment | Jul 19, 2018 | Issued |
Array
(
[id] => 13841395
[patent_doc_number] => 20190024182
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-24
[patent_title] => Sensitivity Markers and Uses for CDK7 Inhibitors in Breast Cancers
[patent_app_type] => utility
[patent_app_number] => 16/038283
[patent_app_country] => US
[patent_app_date] => 2018-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8008
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16038283
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/038283 | Sensitivity markers and uses for CDK7 inhibitors in breast cancers | Jul 17, 2018 | Issued |
Array
(
[id] => 16808350
[patent_doc_number] => 20210130903
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => TARGETING CHROMOSOMAL INSTABILITY AND DOWNSTREAM CYTOSOLIC DNA SIGNALING FOR CANCER TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/629512
[patent_app_country] => US
[patent_app_date] => 2018-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38297
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16629512
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/629512 | Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment | Jul 9, 2018 | Issued |
Array
(
[id] => 15321131
[patent_doc_number] => 20200000895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 16/030725
[patent_app_country] => US
[patent_app_date] => 2018-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35951
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16030725
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/030725 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | Jul 8, 2018 | Issued |
Array
(
[id] => 13522125
[patent_doc_number] => 20180312605
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-01
[patent_title] => ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
[patent_app_type] => utility
[patent_app_number] => 16/028662
[patent_app_country] => US
[patent_app_date] => 2018-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39906
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16028662
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/028662 | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) | Jul 5, 2018 | Issued |
Array
(
[id] => 16268823
[patent_doc_number] => 20200270310
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => MAFG AS A POTENTIAL THERAPEUTIC TARGET TO RESTORE CHEMOSENSITIVITY IN PLATINUM-RESISTANT CANCER CELLS
[patent_app_type] => utility
[patent_app_number] => 16/647368
[patent_app_country] => US
[patent_app_date] => 2018-07-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17101
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647368
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/647368 | MAFG AS A POTENTIAL THERAPEUTIC TARGET TO RESTORE CHEMOSENSITIVITY IN PLATINUM-RESISTANT CANCER CELLS | Jul 3, 2018 | Abandoned |
Array
(
[id] => 13795825
[patent_doc_number] => 20190011451
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-10
[patent_title] => METHODS AND COMPOSITIONS FOR ASSAYING BLOOD LEVELS OF LEGUMAIN
[patent_app_type] => utility
[patent_app_number] => 16/025607
[patent_app_country] => US
[patent_app_date] => 2018-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10231
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16025607
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/025607 | METHODS AND COMPOSITIONS FOR ASSAYING BLOOD LEVELS OF LEGUMAIN | Jul 1, 2018 | Abandoned |
Array
(
[id] => 16016073
[patent_doc_number] => 20200182879
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => DIAGNOSIS AND TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 16/624654
[patent_app_country] => US
[patent_app_date] => 2018-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16525
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16624654
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/624654 | Diagnosis and treatment of cancer | Jun 21, 2018 | Issued |
Array
(
[id] => 17178641
[patent_doc_number] => 11155876
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-26
[patent_title] => K-ras mutations and anti-EGFr antibody therapy
[patent_app_type] => utility
[patent_app_number] => 16/014056
[patent_app_country] => US
[patent_app_date] => 2018-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 11896
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014056
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/014056 | K-ras mutations and anti-EGFr antibody therapy | Jun 20, 2018 | Issued |
Array
(
[id] => 17287101
[patent_doc_number] => 11203641
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-21
[patent_title] => Screening for anti-cancer compounds using netrin-1 activity
[patent_app_type] => utility
[patent_app_number] => 16/014529
[patent_app_country] => US
[patent_app_date] => 2018-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 40
[patent_no_of_words] => 15889
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 242
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014529
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/014529 | Screening for anti-cancer compounds using netrin-1 activity | Jun 20, 2018 | Issued |
Array
(
[id] => 13461701
[patent_doc_number] => 20180282393
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-04
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 16/009301
[patent_app_country] => US
[patent_app_date] => 2018-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009301
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/009301 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | Jun 14, 2018 | Issued |
Array
(
[id] => 13461703
[patent_doc_number] => 20180282394
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-04
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 16/009330
[patent_app_country] => US
[patent_app_date] => 2018-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52068
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009330
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/009330 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | Jun 14, 2018 | Issued |
Array
(
[id] => 15831975
[patent_doc_number] => 20200131269
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT BIND TO BTN1A1 OR BTN1A1-LIGANDS
[patent_app_type] => utility
[patent_app_number] => 16/618764
[patent_app_country] => US
[patent_app_date] => 2018-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61324
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16618764
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/618764 | Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands | Jun 4, 2018 | Issued |